Skip to content
DraconiticResearch
Search Sources API
181,716 studies31 sourcesUpdated 38 min ago
Peer-reviewedCC BY 4.0Frontiers in Immunology

Review on the significance and clinical application of anti-p53 autoantibody detection

  • Fan Bu1
  • Zhe-Nan Ling2
  • Pei Li3
  • Bin Zhou4
  • Wang-Yu Zhu5
  • Jiu-Li Wang6
  • Xiang Liu7
  • Tian-Yu Zhu8
  • Yi-An Du9
  • Qiu-Lei Lang10
  • Liu-Hui Zhou1
  • Zi-Yan Jin1
5 more authors
  • Wen-Jing Wang1
  • Yi-Xuan Li1
  • Yu-Zhen Zhang1
  • Xia-Ying Du1
  • Zhi-Qiang Ling1
10 affiliations
  1. 1Zhejiang Cancer Institute, Zhejiang Cancer Hospital
  2. 2Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine
  3. 3Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, High-Tech Zone
  4. 4Department of General Surgery, Taixing People’s Hospital, Yangzhou University
  5. 5Cell and Molecular Biology Laboratory, Zhoushan Hospital
  6. 6Department of Medical Oncology, Bozhou Hospital of Traditional Chinese Medicine
  7. 7Department of Laboratory Medicine, Tongde Hospital of Zhejiang Province
  8. 8Department of Surgery, Jinhua People’s Hospital, Jindong District
  9. 9Department of Surgery, Zhejiang Hospital
  10. 10Department of Molecular Diagnostics, Hangzhou Lianchuan Biotechnology Co.
Read full textPDFDOICite

Abstract

As a critical tumor suppressor gene, mutations in p53 often contribute to the initiation and progression of cancer. Anti-p53 autoantibody (p53-AAb), produced by the immune system in response to mutated p53 protein, can be detected in the blood during early stages of tumor development. As a non-invasive biomarker, p53-AAb demonstrates potential for early screening, auxiliary diagnosis, prognosis evaluation, and treatment monitoring across various cancer types. Based on current literature and evidence-based medical data, this Review Article provides an overview of the scientific rationale, technical aspects, and clinical applications of p53-AAb testing. It summarizes practical considerations to guide scientific research and clinical practice, with the aim of promoting standardized utilization of this biomarker.

Related

  1. Efgartigimod in the treatment of severe Guillain–Barre syndrome with overlapping autoantibody syndrome: a case report and updated clinical review
    Yueqi Wang, Siqi Wang, Huijuan Fan +6
    ImmunotherapyPeer-reviewedLicence not statedFull textNeurologyPMC
  2. Beyond the Mandibular Canal: A Narrative Review of Inferior Alveolar Nerve Variations and Their Clinical Significance
    Evgenia Moschogianni, George Triantafyllou, Alexandros Samolis +4
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. The Role of the OBSCN Gene in Cardiomyopathy: A Review of Molecular Mechanisms and Clinical Significance
    Jingxiang Chen, Xiaoyun Sun, Sidi Wu +4
    Journal of cardiovascular development and diseasePeer-reviewedCC BYFull textCardiovascular medicineEurope PMC
  4. Clinical significance of intramammary lymph nodes in female primary breast cancer: a systematic review and meta-analysis
    Zijun Zhao, Xiangyu Wang, Wenxiang Zhang +9
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textOncologyCrossref
  5. Clinical significance of human metapneumovirus detection in critically ill adults with lower respiratory tract infections
    Natacha Kapandji, Michael Darmon, Sandrine Valade +5
    Annals of Intensive CarePeer-reviewedCC BYFull text19 citedEpidemiology & public healthHAL

Cite

BibTeXRIS
BibTeX
@article{bu2026review,
  title = {{Review on the significance and clinical application of anti-p53 autoantibody detection}},
  author = {Fan Bu and Zhe-Nan Ling and Pei Li and Bin Zhou and Wang-Yu Zhu and Jiu-Li Wang and Xiang Liu and Tian-Yu Zhu and Yi-An Du and Qiu-Lei Lang and Liu-Hui Zhou and Zi-Yan Jin and Wen-Jing Wang and Yi-Xuan Li and Yu-Zhen Zhang and Xia-Ying Du and Zhi-Qiang Ling},
  journal = {Frontiers in Immunology},
  year = {2026},
  month = oct,
  doi = {10.3389/fimmu.2026.1910252},
  url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1910252/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Review on the significance and clinical application of anti-p53 autoantibody detection
AU  - Fan Bu
AU  - Zhe-Nan Ling
AU  - Pei Li
AU  - Bin Zhou
AU  - Wang-Yu Zhu
AU  - Jiu-Li Wang
AU  - Xiang Liu
AU  - Tian-Yu Zhu
AU  - Yi-An Du
AU  - Qiu-Lei Lang
AU  - Liu-Hui Zhou
AU  - Zi-Yan Jin
AU  - Wen-Jing Wang
AU  - Yi-Xuan Li
AU  - Yu-Zhen Zhang
AU  - Xia-Ying Du
AU  - Zhi-Qiang Ling
PY  - 2026
DA  - 2026/10/06
JO  - Frontiers in Immunology
DO  - 10.3389/fimmu.2026.1910252
UR  - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1910252/full
AB  - As a critical tumor suppressor gene, mutations in p53 often contribute to the initiation and progression of cancer. Anti-p53 autoantibody (p53-AAb), produced by the immune system in response to mutated p53 protein, can be detected in the blood during early stages of tumor development. As a non-invasive biomarker, p53-AAb demonstrates potential for early screening, auxiliary diagnosis, prognosis evaluation, and treatment monitoring across various cancer types. Based on current literature and evidence-based medical data, this Review Article provides an overview of the scientific rationale, technical aspects, and clinical applications of p53-AAb testing. It summarizes practical considerations to guide scientific research and clinical practice, with the aim of promoting standardized utilization of this biomarker.
SN  - 1664-3224
ER  -